Illumina appoints Daniel Skovronsky to Board of Directors
Illumina named Daniel M. Skovronsky to its Board of Directors, effective June 16. His extensive background in drug discovery and leading large R&D portfolios is expected to strengthen Illumina's innovation strategy in precision medicine.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day